Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Treatment refractory schizophrenia]

J M Vanelle1

  • 1Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre hospitalier Sainte-Anne, Paris.

L'Encephale
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The therapeutic alliance in the initial stages of the management of depression by the general practitioner].

L'Encephale·2008
Same author

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.

The American journal of psychiatry·2001
Same author

Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia.

Neuropsychobiology·2001
Same author

[Obsessional neurosis. Diagnosis, treatment].

La Revue du praticien·2000
Same author

[Risperidone-induced tardive dystonia: a case of torticollis].

L'Encephale·1999
Same author

Controlled efficacy study of fluoxetine in dysthymia.

The British journal of psychiatry : the journal of mental science·1997
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Treatment-refractory schizophrenia presents diagnostic challenges due to inconsistent criteria and prevalence estimates. Identifying factors associated with poor outcomes is crucial for effective management of resistant schizophrenia.

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Context:

  • Historically, insulin therapy was used for resistant schizophrenia.
  • Classical neuroleptics improved outcomes but did not resolve all cases, leading to the definition of treatment-refractory schizophrenia.
  • Challenges in defining treatment-refractory schizophrenia include diagnostic variability, outcome assessment, treatment consensus, and differentiating resistance from chronicity or severity.

Purpose:

  • To review the definition and diagnostic challenges of treatment-refractory schizophrenia.
  • To explore existing criteria for treatment-refractory schizophrenia.
  • To discuss factors associated with poor outcomes and therapeutic approaches.

Summary:

  • Three sets of criteria exist for treatment-refractory schizophrenia (Kane et al., May et Dencker, Brenner Dencker et al.).

Related Experiment Videos

  • Prevalence estimates for treatment-refractory schizophrenia vary widely (5-25%) due to diagnostic inconsistencies.
  • Hypothesized factors for poor outcomes include male sex, early onset, symptom severity (negative, thought disorder), absence of affective syndrome, CT abnormalities, and treatment-related factors.

    • Impact:

    • Highlights the complexities in diagnosing and understanding treatment-refractory schizophrenia.
    • Underscores the need for standardized criteria and further research into prevalence and contributing factors.
    • Emphasizes a multimodal therapeutic approach including neuroleptic drugs, institutional support, and family involvement.